Eurosurveillance banner




Announcements
Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Weekly Release  1997: Volume 1/ Issue 29 Article 2 Printer friendly version
Back to Table of Contents
Previous Next

Eurosurveillance, Volume 1, Issue 29, 13 November 1997
Articles

Citation style for this article: Handysides S. The United States recommends immunisation against varicella for children. Should Europe?. Euro Surveill. 1997;1(29):pii=1026. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=1026

The United States recommends immunisation against varicella for children. Should Europe?

Universal immunisation against varicella of children aged 12 to 18 months is recommended in the US but only 20% of 2 year olds have been vaccinated, according to an editorial (1) accompanying two papers on varicella in last week’s JAMA (2,3). A live attenuated vaccine against varicella - the virus that causes chickenpox and shingles (herpes zoster) - became available in the United States (US) two years ago, but is not licensed for universal use in Europe.

One of the papers (2) examined the effectiveness of varicella vaccine in an outbreak of chickenpox that arose in a day care centre for children aged under 6 years. Of 148 children with no history of varicella, 81 (55%) developed disease. Among 66 children who had received the vaccine, 9 (14%) developed varicella compared with 72 (88%) of the 82 unvaccinated children (vaccine efficacy was 86% overall, and 100% against moderate/severe disease). Cases who had been vaccinated had milder disease and were absent from the centre for fewer days than unvaccinated cases. The results provide reassurance about the vaccine’s stability: it must be stored in a frost-free freezer at -15°C or less and used within 30 minutes of reconstitution (2).

None of the children had received varicella vaccine more than 18 months earlier (2), so this study provided no data on the duration of immunity, but other data indicate that it may last for at least 20 years (1). A major concern about switching reliance from immunity acquired through natural infection to immunity acquired through immunisation is that, as immunisation reduces the incidence of the infection, people become less likely to have natural boosts to their immunity through subsequent exposures to infected people. Increasing numbers of adults - in whom the disease is often more severe, and in whom (currently) 55% of varicella deaths occur - might become susceptible to varicella. On the other hand, some evidence suggests that vaccinees may be less likely to develop herpes zoster than people who had varicella (1).

The editorial concludes that the evidence about the benefits of immunisation against varicella is sufficient to urge doctors (certainly in the US) to "just do it!". The situation in Europe is somewhat different. Austria, France, Germany, Greece, Italy, Luxembourg, Portugal and Switzerland have licensed varicella vaccine for use in high risk groups and their contacts only. One thing seems clear: if universal childhood immunisation were to be introduced coverage would have to be high, aiming to eliminate circulating infection. Other strategies might be considered - immunisation of children with impaired immunity (4) or healthy adolescents with no history of chickenpox (3), or of health care workers (4).

References :
  1. Shapiro ED, LaRussa PS. Vaccination for varicella - just do it! JAMA 1997; 278: 1529-30
  2. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278: 1495-9
  3. Wallace MR, Chamberlin CJ, Zerboni L, Sawyer MH, Oldfield EC, Olson PE, et al. Reliability of a history of previous varicella infection in adults. JAMA 1997; 278: 1520-2
  4. Gray AM, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccine for health care workers. Epidemiol Infect 1997; 119: 209-20

Reported by Stuart Handysides (shandysi@phls.co.uk) PHLS Communicable Disease Surveillance Centre, England

back to top



Back to Table of Contents
Previous Next

Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.